益肾舒筋方治疗纤维肌痛综合征
益肾舒筋方治疗纤维肌痛综合征的随机对照临床试验及机制研究
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Juan Jiao
- 电话号码:010-88001132
- 邮箱:jiao.juan@hotmail.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国
- 招聘中
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
-
接触:
- Juan Jiao
- 电话号码:8618611511082
- 邮箱:jiao.juan@hotmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
纳入标准:
- 符合2016年美国风湿病学会制定的纤维肌痛分类标准的原发性纤维肌痛患者。
- 中医证型为肝气郁结、阴血不足,或肝肾阴虚。
- 年龄在18岁及以上,75岁及以下。
- 疼痛VAS评分≥4。
- 未服用FM治疗药物或未使用FM治疗方案超过1个月。
- 签署知情同意书。
排除标准:
- 患有严重抑郁或焦虑的患者;
- 患有心脑血管、肝、肾和造血系统等其他严重原发疾病及血栓性疾病的患者;
- 哺乳期或孕妇;
- 对治疗成分过敏的患者;
- 由其他疾病(如糖尿病性疼痛或带状疱疹后神经痛)引起的严重疼痛患者;
- 近期参加过相同适应症临床试验的患者;
- 男性、右利手或有MRI禁忌症的患者不进行MRI扫描。
禁忌症包括:
神经系统疾病史:脑肿瘤、中风、癫痫、创伤性脑损伤、多发性硬化症等。
不兼容的植入物:心脏起搏器、除颤器、某些类型的动脉瘤夹、人工耳蜗、神经刺激器等。
体内存在金属异物:假牙、眼眶内金属碎片、某些身体区域的弹片等。
幽闭恐惧症。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂组
安慰剂含有原仿单十分之一的剂量。
它与益肾舒筋汤采用相同的颗粒袋包装,确保安慰剂表现出与实际药品相同的颜色、质地、味道和气味。
安慰剂组患者每次服用2袋安慰剂颗粒,每日两次,持续12周。
|
安慰剂含有原始配方十分之一的剂量。
其包装与益肾舒筋汤相同的颗粒袋,确保安慰剂与实际药物表现出相同的颜色、质地、味道和气味。
安慰剂组的患者每次接受2袋安慰剂颗粒,每日两次,持续12周。
|
|
实验性的:益肾舒筋汤组
益肾舒筋汤组患者每次服用益肾舒筋汤2袋,每日2次,连续治疗12周。
|
益肾舒筋汤组患者每次服用益肾舒筋汤2袋,每日2次,连续服用12周。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The change of the Brief Pain Inventory (BPI) from baseline.
大体时间:Baseline, week 2, week 4, week 8, week 12 and week 24
|
The Brief Pain Inventory (BPI) evaluates the severity of pain and pain-related interference with daily functioning.
The BPI total and subscale scores range from 0 to 10, with higher scores indicating greater pain intensity and more significant interference with daily activities.
|
Baseline, week 2, week 4, week 8, week 12 and week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
第 12 周评估的全球变化印象 (PGIC) 问卷。
大体时间:第 12 周。
|
调查问卷确定从研究开始到结束期间整体症状状态的任何变化(评分范围,1 [非常好转] 到 7 [非常糟糕)。
|
第 12 周。
|
|
通过结构MRI测量的大脑形态
大体时间:研究开始前和结束时(0周,12周)。
|
旨在通过结构MRI比较纤维肌痛患者治疗前后脑结构和形态的变化。
图像采用西门子3.0T Skyra扫描仪(西门子;德国慕尼黑)使用快速扰相梯度回波序列获取。
图像包含全脑、灰质、白质、基于图集的感兴趣区域,用于患者组和健康对照组。
结构MRI图像使用CAT 12软件(版本12.7,
r1700)进行处理。
具体而言,基于体素的形态测量流程包括初始和精细的体素处理。
|
研究开始前和结束时(0周,12周)。
|
|
通过功能MRI测量的脑功能连接性
大体时间:研究开始前及结束时(0周、12周)。
|
比较纤维肌痛患者治疗前后脑部连接性和代谢功能的变化,通过功能性MRI。
扫描序列在影像专业人员的指导下设置,同时确保参与者闭眼但清醒状态下进行MRI扫描;头部任何方向的平移不超过1.5mm,任何方向的旋转不超过1.5°。
|
研究开始前及结束时(0周、12周)。
|
|
The change of Fibromyalgia Symptom Scale scores (Widespread Pain Index [WPI] and Symptom Severity Score [SSS]) from baseline.
大体时间:Baseline, week 2, week 4, week 8, week 12 and week 24
|
This scale consists of two subdomains to evaluate the overall severity of fibromyalgia according to the ACR fibromyalgia diagnostic criteria. The Widespread Pain Index (WPI) assesses the extent and diffuseness of body pain, with scores ranging from 0 to 19. Higher scores indicate more widespread, diffuse pain distribution across the body. The Symptom Severity Score (SSS) evaluates the severity of core accompanying fibromyalgia symptoms, with total scores ranging from 0 to 12. Higher scores represent greater severity of general somatic and associated symptomatic burden. |
Baseline, week 2, week 4, week 8, week 12 and week 24
|
|
The change of the revised Fibromyalgia Impact Questionnaire (FIQR) from baseline.
大体时间:Baseline, week 2, week 4, week 8, week 12 and week 24
|
A self-administered questionnaire with 10 subscales, measuring fibromyalgia symptoms and function domains.
FIQR total score ranges from 0 to 100, with higher scores indicating more severe symptoms.
|
Baseline, week 2, week 4, week 8, week 12 and week 24
|
|
The change of the Multidimensional Fatigue Inventory-20 (MFI-20) from baseline.
大体时间:Baseline, week 2, week 4, week 8, week 12 and week 24
|
The Multidimensional Fatigue Inventory-20 (MFI-20) measures fatigue severity.
The MFI-20 total score ranges from 0 to 80, with higher scores indicate more severe fatigue.
|
Baseline, week 2, week 4, week 8, week 12 and week 24
|
|
The change of the Beck II Depression Inventory(BDI) from baseline.
大体时间:Baseline, week 2, week 4, week 8, week 12 and week 24
|
The Beck II Depression Inventory (BDI) assesses the severity of depressive symptoms.
Scores range from 0 to 39, with higher scores indicate a greater degree of depression severity.
|
Baseline, week 2, week 4, week 8, week 12 and week 24
|
|
The change of the Perceived Stress Scale (PSS) from baseline.
大体时间:Baseline, week 2, week 4, week 8, week 12 and week 24
|
The Perceived Stress Scale (PSS) is for measuring the perception of stress and current levels of experienced stress.
Scores range from 0 to 56, with higher total score indicating a greater degree of symptom severity.
|
Baseline, week 2, week 4, week 8, week 12 and week 24
|
|
The change of the Short Form-36 Health Status Questionnaire (SF-36) from baseline.
大体时间:Baseline, week 2, week 4, week 8, week 12 and week 24
|
The Short Form-36 Health Status Questionnaire (SF-36), which measured health-related quality of life (range, 0 to 100, with higher scores indicating better perceived health status).
|
Baseline, week 2, week 4, week 8, week 12 and week 24
|
|
Serum concentrations of inflammatory cytokines, oxidative stress biomarkers and circulating bile acids
大体时间:Before and at the end of the study ( 0, 12 weeks ).
|
Serum IL-6, TNF-α, HMGB1 were tested by ELISA; serum MDA, GSH were detected using biochemical colorimetric method; circulating bile acid components were quantified with liquid chromatography-mass spectrometry (LC-MS).
All blood samples were collected at baseline (0 week) and study endpoint (12 weeks).
|
Before and at the end of the study ( 0, 12 weeks ).
|
|
Fecal relative abundance of intestinal microbiota, fecal bile acid concentration and fecal short-chain fatty acid concentration
大体时间:Before and at the end of the study ( 0, 12 weeks ).
|
Intestinal flora composition was profiled by 16S rRNA high-throughput sequencing; fecal bile acids and short-chain fatty acids were both determined via LC-MS/MS technology.
Fecal specimens were collected at baseline (0 week) and study endpoint (12 weeks).
|
Before and at the end of the study ( 0, 12 weeks ).
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.